2800 Woodlawn Drive
Suite 129
Honolulu, HI 96822
United States
808 457 1400
https://www.cardaxpharma.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 10
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. David G. Watumull | Chairman & CEO | 214.96k | N/A | 1950 |
Mr. David M. Watumull | COO & CFO | 162.11k | N/A | 1982 |
Mr. Gilbert Shin | Vice President of Retail Sales & Marketing | N/A | N/A | N/A |
Cardax, Inc., a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. It offers ZanthoSyn, an inflammatory supplement for health and longevity that provides astaxanthin with enhanced absorption and purity. The company sells ZanthoSyn primarily through e-commerce and wholesale channels. It is also developing CDX-101, an astaxanthin pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, with a target indication of severe hypertriglyceridemia; and CDX-301, a zeaxanthin pharmaceutical candidate for macular degeneration. Cardax, Inc. is based in Honolulu, Hawaii.
Cardax, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.